Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal ...

Former ABC 6 anchor Stacia Naquin is staying in central Ohio, joining the Statehouse press corps for a Cleveland television station. Naquin announced her departure as an anchor at ABC 6 and sister ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

Jan 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...

Galapagos has never been a company to sit still for long, but—even by its own standards—the decision to split in two while waving goodbye to 40% of its employees and a long-standing Gilead ...

Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...

Gilead Sciences (GILD) closed the most recent trading day at $91.09, moving +0.44% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.09%. Elsewhere ...

For 14 years, scientists have been growing a tree akin to the Judean balsam — the source of the balm of Gilead — but with no modern counterpart. For 14 years, scientists have been growing a ...